VALNEVA SE (AYJ.DE) Stock Overview
Europe - FRA:AYJ - FR0004056851 - Common Stock
AYJ.DE Key Statistics, Chart & Performance
The current stock price of AYJ.DE is 3.87 EUR. In the past month the price decreased by -22.32%. In the past year, price increased by 46.92%.
AYJ.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.36 | 343.77B | ||
| AMG.DE | AMGEN INC | 13.34 | 134.70B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.9 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.13 | 125.00B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.66 | 92.11B | ||
| 1AE.DE | ARGENX SE | 95.94 | 43.89B | ||
| ARGX.BR | ARGENX SE | 96.45 | 44.12B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.66B | ||
| IDP.DE | BIOGEN INC | 9.31 | 18.79B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.99B | ||
| 0QF.DE | MODERNA INC | N/A | 8.39B | ||
| 1EXEL.MI | EXELIXIS INC | 17.15 | 8.26B |
Related stock screener links
About AYJ.DE
Company Profile
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 700 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
Company Info
VALNEVA SE
6 rue Alain Bombard
Saint-Herblain PAYS DE LA LOIRE FR
Employees: 700
Phone: 33228073710
VALNEVA SE / AYJ.DE FAQ
What does AYJ do?
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company is headquartered in Saint-Herblain, Pays De La Loire and currently employs 700 full-time employees. The company went IPO on 2007-06-28. The firm's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The firm has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The firm is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
What is the current price of AYJ stock?
The current stock price of AYJ.DE is 3.87 EUR. The price decreased by -2.07% in the last trading session.
Does VALNEVA SE pay dividends?
AYJ.DE does not pay a dividend.
How is the ChartMill rating for VALNEVA SE?
AYJ.DE has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of VALNEVA SE (AYJ.DE) based on its PE ratio?
VALNEVA SE (AYJ.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).
Should I buy AYJ stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AYJ.DE.
AYJ.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to AYJ.DE. When comparing the yearly performance of all stocks, AYJ.DE is one of the better performing stocks in the market, outperforming 91.74% of all stocks.
AYJ.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to AYJ.DE. AYJ.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
AYJ.DE Financial Highlights
Over the last trailing twelve months AYJ.DE reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -95.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.09% | ||
| ROE | -45.87% | ||
| Debt/Equity | 0.8 |
AYJ.DE Forecast & Estimates
10 analysts have analysed AYJ.DE and the average price target is 7.04 EUR. This implies a price increase of 81.96% is expected in the next year compared to the current price of 3.87.
For the next year, analysts expect an EPS growth of -580.55% and a revenue growth 4.16% for AYJ.DE